Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500  ( anti-CD40L mAb )  for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congress - Tonix Pharmaceuticals  ( NASDAQ:TNXP )